Adjuvant Pembrolizumab for Stage IIB or IIC Melanoma

Full Article URL: <a target="_blank" href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2845147">https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2845147
Textarea URL (this page): <a href="https://textarea.nl/i/eNrLKCkpKLbS189KzE3MSy0pzy_K1kvOz9XPyi8tykvMKUaWyC9IzdNPK83JSSwqyUzOSdU3sjAxNTQxBwCOIRlh_2026-02-17">https://textarea.nl/i/eNrLKCkpKLbS189KzE3MSy0pzy_K1kvOz9XPyi8tykvMKUaWyC9IzdNPK83JSSwqyUzOSdU3sjAxNTQxBwCOIRlh_2026-02-17
Source: https://jamanetwork.com/rss/site_214/187.xml
Jamanetwork.com Open: https://jamanetwork.com/journals/jamanetworkopen
Publication date: 2026-02-17 00:00:00
Last retrieval: 2026-02-18 06:45:29.189555

00:00 - 17 Feb 2026

This secondary analysis of a randomized clinical trial assesses new skin cancers, recurrence-free survival with new melanomas considered events, and immune-mediated severe skin reactions among patients receiving pembrolizumab or placebo for stage II melanoma.